Wedbush Raises BioCryst Pharmaceuticals' 2025 EPS Forecast

Summary

Wedbush has raised its FY2025 earnings estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX) to $0.14 per share, up from $0.13. The firm maintains an ‘outperform’ rating with a price target of $18.00. Consensus estimates for the current full-year earnings stand at ($0.36) per share. Other analysts have also adjusted their ratings and price targets for BCRX, with a consensus rating of ‘buy’ and a target price of $16.70. BioCryst reported $0.15 EPS for the last quarter, exceeding estimates, with revenue up 49.5% year-over-year.Market Beat

Impact Analysis

This event is at the company level as it specifically impacts BioCryst Pharmaceuticals. The increase in earnings estimates by Wedbush suggests confidence in BioCryst’s financial performance, which could positively influence investor sentiment and potentially boost the company’s stock price. The ‘outperform’ rating and target price of $18.00 align with other favorable analyst adjustments, indicating a broader positive outlook for BioCryst Pharmaceuticals. Historical context shows a pattern of positive revisions: RBC and Evercore have also previously raised their price targets and ratings for the company.Market Beat+ 3 The company’s recent EPS performance exceeding estimates with significant revenue growth supports this optimistic view. Risks might include market volatility and unexpected operational challenges that could affect future earnings. Investors may find opportunities in purchasing BioCryst Pharmaceuticals stock, given the upward revisions and positive consensus, but should consider these potential risks.